High level of CD10 expression is associated with poor overall survival in patients with head and neck cancer

Li, Q.; Wang, Y.; Xu, Le; Wang, L.; Guo, Yifan; Guo, Chuanbin

doi:10.1016/j.ijom.2020.07.037

Cited by 8 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, a study by Li et al reported that higher CD10 expression in head and neck squamous cell carcinoma (HNSCC) correlates with worse overall survival (OS) and recurrence-free survival (RFS). The study further reveals a correlation between CD10 expression and increased IL-6/ IL-8-mediated M1 macrophage activity, which may explain the poor prognosis observed in HNSCC cases (Li et al, 2021). In esophageal squamous cell carcinoma (ESCC), research by Lee et al has revealed that 30% of the examined ESCC samples exhibited CD10 expression in cancer cells to varying degrees.…”

Section: Cd10 and Nonhematologic Tumorsmentioning

confidence: 70%

A comprehensive review of the literature on CD10: its function, clinical application, and prospects

Wang,

Xiao,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

CD10, a zinc-dependent metalloprotease found on the cell surface, plays a pivotal role in an array of physiological and pathological processes including cardiovascular regulation, immune function, fetal development, pain response, oncogenesis, and aging. Recognized as a biomarker for hematopoietic and tissue stem cells, CD10 has garnered attention for its prognostic potential in the progression of leukemia and various solid tumors. Recent studies underscore its regulatory significance and therapeutic promise in combating Alzheimer’s disease (AD), and it is noted for its protective role in preventing heart failure (HF), obesity, and type-2 diabetes. Furthermore, CD10/substance P interaction has also been shown to contribute to the pain signaling regulation and immunomodulation in diseases such as complex regional pain syndrome (CRPS) and osteoarthritis (OA). The emergence of COVID-19 has sparked interest in CD10’s involvement in the disease’s pathogenesis. Given its association with multiple disease states, CD10 is a prime therapeutic target; inhibitors targeting CD10 are now being advanced as therapeutic agents. This review compiles recent and earlier literature on CD10, elucidating its physicochemical attributes, tissue-specific expression, and molecular functions. Furthermore, it details the association of CD10 with various diseases and the clinical advancements of its inhibitors, providing a comprehensive overview of its growing significance in medical research.

show abstract

Section: Cd10 and Nonhematologic Tumorsmentioning

confidence: 70%

A comprehensive review of the literature on CD10: its function, clinical application, and prospects

Wang,

Xiao,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In addition, high levels of CD10 have been found on cells resistant to cisplatin, fluorouracil and radiation in several HNSCC cell lines, including Detroit-562 46 . CD10 is also involved in some signaling pathways, such as the PI3K-Akt pathway, 47,48 which is highly activated in HNSCC 5,49 . CD184 has been described as a membrane receptor mainly expressed on CSCs, also called CXCR4.…”

Section: Discussionmentioning

confidence: 99%

NAD pool as an antitumor target against cancer stem cells in head and neck cancer

Navas

Blanco-Alcaina

Suárez-Martínez

et al. 2023

J Exp Clin Cancer Res

View full text Add to dashboard Cite

SummaryHead and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that affect different anatomical locations. Despite this heterogeneity, HNSCC treatment depends on the anatomical location, TNM stage and resectability of the tumor. Classical chemotherapy is based on platinum-derived drugs (cisplatin, carboplatin and oxaliplatin), taxanes (docetaxel, paclitaxel) and 5-fluorouracil1. Despite advances in HNSCC treatment, the rate of tumor recurrence and patient mortality remain high. Therefore, the search for new prognostic identifiers and treatments targeting therapy-resistant tumor cells is vital. Our work demonstrates that there are different subgroups with high phenotypic plasticity within the CSC population in HNSCC. CD10, CD184, and CD166 may identify some of these CSC subpopulations with NAMPT as a common metabolic gene for the resilient cells of these subpopulations. We observed that NAMPT reduction causes a decrease in tumorigenic and stemness properties, migration capacity and CSC phenotype through NAD pool depletion. However, NAMPT-inhibited cells can acquire resistance by activating the NAPRT enzyme of the Preiss-Handler pathway. We observed that coadministration of the NAMPT inhibitor with the NAPRT inhibitor cooperated inhibiting tumor growth. The use of an NAPRT inhibitor as an adjuvant improved NAMPT inhibitor efficacy and reduced the dose and toxicity of these inhibitors. Therefore, it seems that the reduction in the NAD pool could have efficacy in tumor therapy. This was confirmed by in vitro assays supplying the cells with products of inhibited enzymes (NA, NMN or NAD) and restoring their tumorigenic and stemness properties. In conclusion, the coinhibition of NAMPT and NAPRT improved the efficacy of antitumor treatment, indicating that the reduction in the NAD pool is important to prevent tumor growth.

show abstract

“…The TME established by this procedure has a vital role in evolutionary and ecological processes in pancreatic cancer ( Ren et al, 2018 ). The correlation between interleukin (IL)-6/IL-8-mediated M1 macrophage activity and CD10 expression could potentially explain the poor prognosis of HNSC ( Li et al, 2020 ). Therefore, the exploration of intratumor immunity and stromal scores is beneficial to provide valuable promising guidance for tumor immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

P2RY14 Is a Potential Biomarker of Tumor Microenvironment Immunomodulation and Favorable Prognosis in Patients With Head and Neck Cancer

Li¹,

Xu²,

Li³

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

The tumor microenvironment (TME) has a crucial role in tumor development, progression, and treatment response. Yet, the exact interaction between cancer biology and the TME is not fully understood. The following study analyzed the correlation between immune/stromal/estimate scores and survival prognosis in head and neck squamous cell carcinoma (HNSC) using a bioinformatic method. As a result, a predictive biomarker, UDP-glucose-specific G(i) protein-coupled P2Y receptor (P2RY14), was discovered. The potential role of P2RY14-driven signaling pathways in the immune-remodeling of TME was then investigated. Briefly, low immune scores were associated with unfavorable prognosis and clinical-stage, larger tumor size, and the down-regulation of P2RY14 in HNSC patients. In addition, the survival analysis showed that HNSC patients with high expression had longer survival than patients with low expression from both TCGA databases and our own patients. We further discovered that P2RY14 is involved in the immune activity in the TME of HNSC; a downregulation of P2RY14 resulted in being an indicator for the conversion of TME status (from immune-dominant to metabolic-dominant status). The intersection analysis of genes co-expressed with P2RY14 indicated that the T-cell receptor signaling pathway and PD-L1 expression and PD-1 checkpoint pathway were candidate signaling pathways driven by the P2RY14 gene in HNSC. Further investigation of immune-associated signaling pathways regulated by P2RY14 may help HNSC patients gain higher immunotherapy benefits.

show abstract

High level of CD10 expression is associated with poor overall survival in patients with head and neck cancer

Cited by 8 publications

References 27 publications

A comprehensive review of the literature on CD10: its function, clinical application, and prospects

A comprehensive review of the literature on CD10: its function, clinical application, and prospects

NAD pool as an antitumor target against cancer stem cells in head and neck cancer

P2RY14 Is a Potential Biomarker of Tumor Microenvironment Immunomodulation and Favorable Prognosis in Patients With Head and Neck Cancer

Contact Info

Product

Resources

About